AMG
FDA Halts Amgen’s Phase 1 Obesity Drug Trial: AMG 513 Study on Hold
Amgen, obesity drug, AMG 513, FDA clinical hold, Phase 1 trial, pharmaceutical setback
Actionable Insights Powered by AI
Amgen, obesity drug, AMG 513, FDA clinical hold, Phase 1 trial, pharmaceutical setback